SAN FRANCISCO — Tryton Medical (Durham, N.C.), a private company, reported it has met its primary endpoints from a pivotal confirmatory study surrounding the acceptable acute safety profile of the Tryton Side Branch Stent for the treatment of coronary bifurcation lesions in vessels appropriate for a ≥2.5mm stent. Results of the study were presented as part of the featured here at the clinical research session at the Transcatheter Cardiovascular Therapeutics (TCT) conference. Read More
